CTLA4 and melanoma: In the Melanoma-GSE91061 (anti–PD-1), Melanoma-PRJNA23709 (anti–PD-1 + anti–CTLA4), and STAD-PRJEB25780 (anti–PD-1) cohorts, the low-risk group had a higher immunotherapy response rate, and the risk scores of responders were significantly lower than those of nonresponders (P < 0.05) (Figures 9D–F), suggesting that these patients may benefit more from anti–PD-1 and anti–CTLA4 therapies.